Please check your internet connection and try again.
# Lennox-Gastaut Syndrome (LGS)
## Overview
Lennox-Gastaut syndrome is a severe form of childhood-onset epilepsy characterized by multiple seizure types, slow spike-wave patterns on EEG, and intellectual impairment. Management requires polytherapy with adjunctive anti-seizure medications (ASMs).
## Primary Indications
Adjunctive therapy for seizures associated with LGS. Primary agents include rufinamide, clobazam, topiramate, felbamate, lamotrigine, and cannabidiol.
## Adult Dosing
* **Rufinamide:** Start 400–800 mg/day in two divided doses; titrate by 400–800 mg every 2 days to a max of 3,200 mg/day.
* **Clobazam:** Start 5–10 mg/day; titrate to 20 mg/day (usually given in two divided doses).
* **Topiramate:** Start 25 mg/day; titrate slowly by 25–50 mg/week to target dose of 200–400 mg/day.
* **Cannabidiol:** Starting dose 5 mg/kg twice daily (10 mg/kg/day); may increase to 10 mg/kg twice daily (20 mg/kg/day) after one week.
## Pediatric Dosing
* **Rufinamide (≥1 year):** Start ~10 mg/kg/day in two divided doses; titrate to target 45 mg/kg/day (not to exceed 3,200 mg/day).
* **Clobazam (≥2 years):** Weight-based; <30 kg: 5 mg/day, reach 20 mg/day. ≥30 kg: 10 mg/day, reach 40 mg/day. Doses >5 mg/day given in two divided doses.
* **Cannabidiol (≥1 year):** Initial 2.5 mg/kg twice daily; increase to maintenance of 10 mg/kg twice daily over 2 weeks.
* **Felbamate:** Used sparingly due to toxicity; typically 15–45 mg/kg/day.
## Dose Adjustments
* **Renal/Hepatic Impairment:** Significant adjustments are required; consult product-specific labeling. Valproate significantly increases plasma concentrations of rufinamide and clobazam; dose reductions are frequently necessary when used concurrently.
## Contraindications
* **General:** Hypersensitivity to active ingredients.
* **Rufinamide:** Familial Short QT syndrome (risk of cardiac arrhythmias).
* **Felbamate:** History of hepatic failure or aplastic anemia.
## Adverse Effects
* **Common:** Somnolence, fatigue, dizziness, irritability, ataxia.
* **Serious:** Status epilepticus, suicidal ideation, hepatotoxicity (felbamate, cannabidiol), rash/Stevens-Johnson syndrome (lamotrigine), and hematologic dyscrasias (felbamate).
## Key Drug Interactions
* **Enzyme Inducers/Inhibitors:** Many LGS agents undergo hepatic metabolism (CYP450).
* **Valproate:** Increases levels of rufinamide and clobazam (active metabolite N-desmethylclobazam).
* **CNS Depressants:** Additive sedation with clobazam and other ASMs.
## Monitoring
* **Clinical:** Seizure frequency logs, mental status changes, signs of suicidal ideation.
* **Laboratory:** Liver function tests (baseline and periodic for cannabidiol and felbamate), CBC (felbamate), and ECG (if using rufinamide and baseline QT is a concern).
## Clinical Pearls
* Therapy is rarely monotherapeutic; most patients require a combination of agents.
* Clobazam is highly effective for drop attacks but carries high risk for tolerance and withdrawal seizures if stopped abruptly.
* Felbamate is reserved for refractory cases due to the black box warning for serious organ toxicity; requires informed consent and strict monitoring.
* *Note:* Exact titration schedules vary by institution-specific protocols and patient tolerability.
***
**Disclaimer:** This information is for educational purposes only. Clinical practice guidelines change frequently. Always verify current prescribing information, package inserts, and local institutional protocols before prescribing or administering any medication.
